<DOC>
	<DOC>NCT01122329</DOC>
	<brief_summary>This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment. Cognitive testing will also be conducted at baseline and day 45.</brief_summary>
	<brief_title>A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable AD (NINDSADRDA criteria(32)) Age 50 90 (inclusive) MMSE range: 10 to 28 Participants may be taking medications for AD, provided that the dose of these medications has been stable for &gt; 90 days Proficiency in English to be able to perform cognitive tests A caregiver must be available to monitor and administer treatment and to accompany the subject to every clinical visit. Inability for any reason to undergo PET/CT scans Previous treatment with AC1202 Allergic to milk or soy Presence of neurodegenerative disease other than AD History of stroke or other injury that could result in cognitive impairment Psychiatric disorder Diabetes mellitus Recent (&lt;90 days) changes to medications prescribed for cognitive reasons or with the potential to impact cognition Irritable bowel syndrome (IBS) or other gastrointestinal conditions that could interfere with treatment compliance Any factor deemed by the investigator to be likely to interfere with study conduction</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>dementia</keyword>
</DOC>